Biotechnology

Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects

HANGZHOU, China, April 4, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has recently completed phase I trials in healthy subjects inChina for its self-developed innovative intestina...

2023-04-04 20:00 2836

iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.

* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids * The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworld.com...

2023-04-04 10:33 2171

AnPac Bio-Medical Science Enters into Asset Purchase Agreement with Easy Hundred Inc.

NEW YORK, April 3, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ: ANPC), a company with operations inthe United States andChina focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform foc...

2023-04-03 21:00 2927

GC Cell and New Management Embarking on a New Chapter

* Securing future growth engine by scouting global talents; AGM resolved new CEOJames Park and CTO Ho-won Kim as internal directors * Setting business goals focusing on change and growth * Proposing a new corporate vision of "Global Creator of Cell & Gene Therapy" YONGIN,South Korea, April 3...

2023-04-03 16:47 2185

Harbour BioMed Reports Full Year 2022 Financial Results

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncolo...

2023-04-03 15:10 3590

The World's Second Approved Biosimilars of Denosumab (MAILISHU)

SHANGHAI, April 3, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that the Denosumab solution for injection (trade name: MAILISHU, project code: 9MW0311), which is developed by its wholly-owned subsidiary T-m...

2023-04-03 13:44 1891

CBC Group Appoints Healthcare Veteran Abbas Hussain as Operating Partner

SINGAPORE, March 31, 2023 /PRNewswire/ -- Singapore-headquartered asset management firm, CBC Group ("CBC"), is pleased to announce the appointment of healthcare industry veteran, Abbas Hussain, as Operating Partner. In this role, Abbas will closely partner with CBC's business teams to identify, ...

2023-04-01 10:00 3681

Hugel Appointed Suk-yong Cha as Executive Chairman and Chairman of the Board Accelerating Transformation into a Global Top-tier Company

- Appointed as Executive Chairman and Chairman of the Board at the General Meeting of Shareholders and Board of Directors meeting on the 30th - Chairman Cha will lead the growth of Hugel based on his aesthetics know-how and experience in pioneering global markets SEOUL, South Korea, March 31, 20...

2023-03-31 20:00 1983

I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2022

* Strategic reprioritization of the Company's pipeline to focus on key clinical assets and overall streamlining of corporate structure and workforce, resulting in a significant reduction in the cash burn rate and in significant pipeline achievements by focus * Thirteen key clinical milestones...

2023-03-31 18:30 4316

Genscript Biotech Reports 2022 Annual Results*

Non-Cell Therapy Achieved 31.4% Adjusted Net Profit Growth Cell Therapy Business Revenue Surged By 70% * Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximatelyUS$490.1 million for the year e...

2023-03-31 08:40 2900

Kintor Pharma Announces 2022 Annual Results and Recent Business Progress

SUZHOU, China, March 30, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended31 Decembe...

2023-03-31 00:33 3233

Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "...

2023-03-30 21:00 1778

ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization

NEWARK, Del., March 30, 2023 /PRNewswire/ -- With more than 10 years of experience in protein development, ACROBiosystems has continuously demonstrated its strength in developing products and services throughout the entire drug development process. As such, ACROBiosystems has begun to narrow its ...

2023-03-30 18:54 1865

Zylox-Tonbridge Announces Financial Results for 2022: Revenue Increases by 87.8% YOY to RMB 334 million and Gross Profit Reaches RMB 253 million

HANGZHOU, China, March 30, 2023 /PRNewswire/ -- On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY ...

2023-03-30 15:49 2053

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product MVR-C5252 targeting malignant glioma obtained the approval from National Medical Products Administration ("NMPA") for Phase I clinical trial inChina on March 29, 2023. Previously, MVR-C5252 also obt...

2023-03-30 08:00 1730

bitBiome and Kaken Pharmaceuticals sign joint research agreement on the discovery of drugs for infectious diseases

-The joint research will use bitBiome's drug discovery platform technology to search for drug candidate substances- TOKYO, March 29, 2023 /PRNewswire/ -- bitBiome, Inc. (Head office: Shinjuku-ku,Tokyo; President: Yuji Suzuki; hereafter 'bitBiome') and Kaken Pharmaceuticals (Head office: Bunkyo-k...

2023-03-29 22:00 2005

Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China

SUZHOU, China, March 28, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 740 subjects recently for...

2023-03-28 21:41 1598

Tigermed Reports Full Year 2022 Results

HANGZHOU, China, March 28, 2023 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions across full lifecycle of global biopharmaceutical and medical device products, announced its an...

2023-03-28 19:09 2154

OncoVent, a Subsidiary of Hepalink, Enters into a License and Distribution Agreement with Orient EuroPharma for the Immunotherapeutic Candidate Oregovomab

SHENZHEN, China, March 28, 2023 /PRNewswire/ -- OncoVent Co., Ltd. ("OncoVent"), a majority-controlled subsidiary of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "Company"), yesterday entered into a license agreement with Orient EuroPharma Co., Ltd. ("OEP"). According to the terms of th...

2023-03-28 15:36 1663

Acepodia to Present Preclinical Data of Gamma Delta T cell Therapy Candidate, ACE2016, an off-the-shelf EGFR-targeting γδ2 T cell therapy against EGFR-expressing solid tumors

ALAMEDA, Calif. and TAIPEI, March 27, 2023 /PRNewswire/ -- Acepodia, a clinical-stage biotechnology company developing first-in-class cell therapies with its unique antibody-cell conjugation (ACC) technology to address gaps in cancer care, today announced the upcoming poster presentation of new ...

2023-03-28 10:00 1558
1 ... 53545556575859 ... 127